Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: A meta-analysis

Sir,

Obsessive-compulsive disorder (OCD) is associated with an estimated lifetime prevalence of 2%. An estimated 50–80% of the patients are treatment-resistant, with either no response or a limited response to adequate trials of selective serotonin reuptake inhibitors (SSRIs) and clomipramine. The American Psychiatric Association (APA) Practice Guidelines recommend augmentation with atypical antipsychotics, an alternate SSRI, mirtazapine, or venlafaxine as second-line treatment options.

Pindolol exerts antihypertensive effects through β-blockade, and is also a potent serotonin 5HT1A presynaptic receptor antagonist. The serotonin 5HT1A receptor is primarily an autoreceptor, and agonism of this receptor downregulates serotonin release. Pindolol augmentation theoretically leads to an increased release of serotonin through the blockade of the 5HT1A receptor.

The APA guidelines note that limited evidence exists to support the use of pindolol as an augmentation strategy, and a meta-analytic review would aid in the evaluation of the current evidence for its use. A meta-analysis is particularly useful in situations where few studies have been performed, especially when those studies have employed small sample sizes. In these situations, a meta-analysis can provide an overall measure of medication efficacy that would be otherwise unavailable, owing to low statistical power. To date, no systematic review or meta-analysis of the literature examining the efficacy of pindolol augmentation has been performed. The purpose of this study was to determine the level of evidence supporting pindolol augmentation of SSRIs and clomipramine for the treatment of OCD, by performing a quantitative review of the literature through the use of meta-analytic techniques.

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed. Ovid Medline, PubMed, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, and review of article references were used to search for all studies examining pindolol augmentation for the treatment of OCD. The search terms included pindolol, beta-blocker, serotonin 5HT1A, and obsessive-compulsive disorder. To maximize the statistical power, all studies that were published in peer-reviewed journals prior to June 30, 2014, were included, regardless of the study design or language of publication. The Yale–Brown Obsessive-Compulsive Scale is the most commonly used measure of OCD severity, and was used as the measure of efficacy in the meta-analysis. The standard meta-analytic techniques were employed for data extraction. Calculations were performed manually, with the use of the Statistical Package for Social Sciences, as a second point of reference. The Pearson correlation coefficient r was used as the effect size measure, given that it was applicable to statistical analyses of repeated measures. Cohen’s d is also commonly used in meta-analytical research, and is easily calculated from r, but is not readily interpretable in repeated
**Table 1: Descriptive data and associated effect sizes of the study**

| Author       | Year | n  | r     | Mean (SD) | Study design          | Pindolol dose                      | Additional concurrent therapy        |
|--------------|------|-----|-------|-----------|-----------------------|------------------------------------|--------------------------------------|
| Blier et al. | 1996 | 13  | 0.35  | 33.90 (9.81) | 3.00 (4.00)          | Single sample, longitudinal        | Fluoxetine (n=4)                      |
|              |      |     |       |           |                       | 2.5 mg to 5 mg p.o b.i.d           | Clomipramine (n=1)                   |
| Koran et al. | 1996 | 8   | 0.35  | 36.57 (12.71) | 3.28 (8.69)          | Single sample, longitudinal        | Clomipramine (n=4)                    |
|              |      |     |       |           |                       | 2.5 mg p.o q.a.m and 5 mg p.o q.h.s or 5 mg p.o b.i.d | Fluoxetine (n=1)                      |
| Dannon et al.| 2000 | 14  | 0.65  | 34.84 (11.84) | 5.00 (3.14)          | Double-blind RCT                   | Paroxetine (n=16)                    |
| Mundo et al. | 1998 | 15  | 0.00  | 28.80 (2.64)  | 0.00*                 | Double-blind RCT                   | Fluvoxamine (n=15)                   |

*Insufficient information provided to calculate SD, YBOCS=Yale-Brown obsessive-compulsive scale, RCT=Randomized controlled trial, SD=Standard deviation

Pindolol augmentation of SSRIs and clomipramine significantly reduced OCD symptoms in the random (t_{(1)}=2.39, r = 0.36, P_{one-tailed} = 0.048, 95% CI = 0.067–0.59) and fixed effects models (k = 4, N = 50, z = 3.18, r = 0.35, P_{one-tailed} = 0.00075, 95% CI = 0.046–0.59). Fail-safe N analysis found the number of new or unretrieved studies averaging nil results, which were required to bring the overall P_{one-tailed} to 0.05, to be N = 8.

When only the randomized placebo-controlled trials were analyzed, P_{one-tailed} pindolol augmentation was associated with a non-statistically significant trend toward reduction of OCD symptoms in the random (t_{(1)}=1.00, r = 0.37, P_{one-tailed} = 0.25, 95% CI = -0.60–0.90) and fixed effect models (k = 2, N = 29, z = 0.88, r = 0.18, P_{one-tailed} = 0.19, 95% CI = -0.23 – 0.54).

Three of the studies reported that no significant adverse effects of pindolol were experienced by patients. The fourth study included in the meta-analysis did not report whether adverse effects were experienced. From the preliminary evidence, it appears that pindolol is a safe treatment option, when used at doses included in the current studies.

The main limitation of this meta-analysis is the small number of studies included, only two of which were randomized controlled trials. However, the major benefit of meta-analytic research is the combination of the results of small studies to calculate the measure of efficacy that would otherwise be unavailable. This meta-analysis provides clinicians with the best available assessment of the utility of pindolol as an augmentation strategy for the treatment of OCD. Medium effect sizes, defined as r = 0.3, were found for the efficacy of pindolol, including in the analysis of solely randomized controlled trials. Although publication bias toward positive results is possible, the fail-safe N of eight studies indicates some tolerance for the unpublished negative studies.

The authors hope the results of this meta-analysis will lead to increased research examining the use of pindolol for OCD, a mental disorder in need of effective treatment options. Although further study is needed to fully characterize the efficacy of pindolol for the treatment of OCD, preliminary evidence suggests that pindolol may be a useful adjunctive medication.

Sean A. Sassano-Higgins, Michele T. Pato
Department of Psychiatry, University of Southern California, Los Angeles, California, USA
Research Letter

Address for correspondence:
Sean Sassano-Higgins, Department of Psychiatry,
Los Angeles County Hospital, OPD #1P10, 2010 Zonal Avenue,
Los Angeles - 90033, California, USA.
E-mail: Sean.sassano-higgins@med.usc.edu

Received: 01-06-2014
Revised: 31-07-2014
Accepted: 11-09-2014

REFERENCES

1. Koran LM, Simpson HB. Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association; 2013.

2. Artigas F, Celada P, Laruelle M, Addil A. How does pindolol improve antidepressant action? Trends Pharmacol Sci 2001;22:224-8.

3. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264‑9.

4. Rosenthal R, Rosnow R. Essentials of Behavioral Research: Methods and Data Analysis. 3rd ed. New York: McGraw-Hill; 2008. p. 663‑90.

5. IBM Corp. IBM SPSS Statistics for Windows. Version 22.0. Armonk, NY: IBM Corp; 2013.

6. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings. Int Clin Psychopharmacol 1996;11:37-44.

7. Koran L, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? J Clin Psychopharmacol 1996;16:253-4.

8. Dannon PN, Saxon Y, Hirschmann S, Lancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: A double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:163-9.

9. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: A double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:219-24.

Access this article online

Quick Response Code:
Website: www.jpharmacol.com
DOI: 10.4103/0976-500X.149144

Announcement

iPhone App

Download iPhone, iPad application

A free application to browse and search the journal’s content is now available for iPhone/iPad. The application provides “Table of Contents” of the latest issues, which are stored on the device for future offline browsing. Internet connection is required to access the back issues and search facility. The application is Compatible with iPhone, iPod touch, and iPad and Requires iOS 3.1 or later. The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8. For suggestions and comments do write back to us.